Anti-Hypertensive Drugs - Brazil

Brazil

In Brazil, the revenue in the Anti-Hypertensive Drugs market is estimated to reach €0.37bn in 2024.
It is anticipated that there will be an annual growth rate (CAGR 2024-2029) of 0.53%, leading to a market volume of €0.38bn by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to €11,400.00m in 2024.
Brazil is experiencing a growing demand for locally produced anti-hypertensive drugs, driven by an aging population and increasing prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Hypertensive Drugs market in Brazil has been growing steadily over the years.

Customer preferences: Brazil has a high prevalence of hypertension, which has led to an increase in demand for anti-hypertensive drugs. Customers prefer drugs that are effective, affordable, and have minimal side effects. In addition, there is a growing demand for generic drugs due to their affordability.

Trends in the market: One of the major trends in the anti-hypertensive drugs market in Brazil is the increasing use of combination therapy. This involves the use of two or more drugs to achieve better blood pressure control. Another trend is the growing popularity of fixed-dose combination drugs, which are convenient and easy to use. The market is also witnessing an increase in the use of calcium channel blockers and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Local special circumstances: Brazil has a universal public healthcare system, which provides free access to essential medicines, including anti-hypertensive drugs. However, the public healthcare system is often overburdened, leading to long waiting times and shortages of drugs. This has led to an increase in demand for private healthcare services, which offer faster access to drugs and better quality care.

Underlying macroeconomic factors: The Brazilian economy has been recovering from a recession, which has led to an increase in disposable income and healthcare spending. In addition, the government has implemented policies to promote the production and use of generic drugs, which has led to an increase in competition and lower prices. However, the market is also facing challenges such as high import taxes and a complex regulatory environment, which can hinder market growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.